Masayuki Hata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4908349/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy. Science, 2020, 369, .	12.6	139
2	The Significance of External Limiting Membrane Status for Visual Acuity in Age-Related Macular Degeneration. American Journal of Ophthalmology, 2010, 150, 27-32.e1.	3.3	112
3	One-Year Result of Aflibercept Treatment on Age-Related Macular Degeneration and Predictive Factors for Visual Outcome. American Journal of Ophthalmology, 2015, 159, 853-860.e1.	3.3	99
4	Detection of Myopic Choroidal Neovascularization Using Optical Coherence Tomography Angiography. American Journal of Ophthalmology, 2016, 165, 108-114.	3.3	79
5	Structural and Functional Analyses in Nonarteritic Anterior Ischemic Optic Neuropathy: Optical Coherence Tomography Angiography Study. Journal of Neuro-Ophthalmology, 2017, 37, 140-148.	0.8	58
6	KUS121, a VCP modulator, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress. Scientific Reports, 2017, 7, 44873.	3.3	25
7	RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2017, 37, 2069-2077.	1.7	21
8	Association of Vascular Versus Avascular Subretinal Hyperreflective Material With Aflibercept Response in Age-related Macular Degeneration. American Journal of Ophthalmology, 2017, 181, 61-70.	3.3	21
9	Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial. PLoS ONE, 2020, 15, e0229068.	2.5	14
10	Ten-year outcomes of 1125 low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan. World Journal of Urology, 2015, 33, 1519-1526.	2.2	12
11	Quantitative comparison of disc rim color in optic nerve atrophy of compressive optic neuropathy and glaucomatous optic neuropathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1609-1616.	1.9	12
12	INCIDENCE AND CAUSES OF VISION LOSS DURING AFLIBERCEPT TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 1320-1328.	1.7	12
13	KUS121, an ATP regulator, mitigates chorioretinal pathologies in animal models ofÂage-related macular degeneration. Heliyon, 2018, 4, e00624.	3.2	9
14	Myeloidâ€resident neuropilinâ€1 promotes choroidal neovascularization while mitigating inflammation. EMBO Molecular Medicine, 2021, 13, e11754.	6.9	9
15	Pachychoroidâ€phenotype effects on 5â€year visual outcomes of antiâ€VEGF monotherapy in polypoidal choroidal vasculopathy. Acta Ophthalmologica, 2022, 100, .	1.1	8
16	Novel Predictors of Visual Outcome in Anti-VEGF Therapy for Myopic Choroidal Neovascularization Derived Using OCT Angiography. Ophthalmology Retina, 2018, 2, 1118-1124.	2.4	6
17	Rescue photodynamic therapy for age-related macular degeneration refractory to anti-vascular endothelial growth factor monotherapy. Photodiagnosis and Photodynamic Therapy, 2022, 38, 102745.	2.6	4
18	A Case of Neuromyelitis Optica Masquerading as Miller Fisher Syndrome. Case Reports in Neurology, 2014, 6, 226-231.	0.7	3

#	Article	IF	CITATIONS
19	Convergence paralysis caused by a localized cerebral infarction affecting the white matter underlying the right frontal eye field. Journal of the Neurological Sciences, 2017, 375, 94-96.	0.6	3
20	Efficacy of combined anti-VEGF and photodynamic therapy for bilateral diffuse uveal melanocytic proliferation. Medicine (United States), 2021, 100, e27578.	1.0	2